Cargando…
A prospective study to validate the expanded timed get-up-and-go in a population with multiple sclerosis
BACKGROUND: Timed 25-foot walk (T25FW) test serves as gold standard in care of persons with multiple sclerosis (PwMS) and as walking measure of regulatory trials. OBJECTIVE: To validate and determine the clinical utility of Expanded Timed Get-Up and Go (ETGUG) as a disability measure in MS. METHODS:...
Autores principales: | Jakimovski, Dejan, Kavak, Katelyn S, Zakalik, Karen, Bromley, Lacey, Ozel, Osman, Qutab, Natasha, Eckert, Svetlana P, Kolb, Channa, Weinstock-Guttman, Bianca |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
SAGE Publications
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9102142/ https://www.ncbi.nlm.nih.gov/pubmed/35571975 http://dx.doi.org/10.1177/20552173221099186 |
Ejemplares similares
-
COVID-19 Vaccination in Multiple Sclerosis and Inflammatory Diseases: Effects from Disease-Modifying Therapy, Long-Term Seroprevalence and Breakthrough Infections
por: Jakimovski, Dejan, et al.
Publicado: (2022) -
Dimethyl Fumarate in the Treatment of Relapsing-Remitting Multiple Sclerosis: Patient Reported Outcomes and Perspectives
por: Ozel, Osman, et al.
Publicado: (2019) -
Multiple Sclerosis in Children: Differential Diagnosis, Prognosis, and Disease-Modifying Treatment
por: Jakimovski, Dejan, et al.
Publicado: (2021) -
Asymptomatic infection after BNT162b2 mRNA COVID-19 vaccination in multiple sclerosis patient
por: Jakimovski, Dejan, et al.
Publicado: (2021) -
Tixagevimab and Cilgavimab (Evusheld™) Prophylaxis Prevents Breakthrough COVID-19 Infections in Immunosuppressed Population: 6-Month Prospective Study
por: Jakimovski, Dejan, et al.
Publicado: (2023)